Oslo/Cape Town, 06 December 2025: Scatec ASA, a leading renewable energy provider, has started commercial operation of the 273 MW Grootfontein solar power plant in South Africa, which will generate predictable revenues from a 20-year power purchase agreement (PPA). “We are proud to commence commercial operations at Grootfontein, reinforcing our strong track record in South Africa. This project builds on our commitment to deliver clean, reliable energy while creating long-term value for local communities and partners. We thank our stakeholders for their continued collaboration and look forward to continuing our support of the energy transition in South Africa,” says Scatec CEO, Terje Pilskog. “Bringing the Grootfontein plant into operation is an important milestone for Scatec and our partners. As our first project in the Western Cape, and...

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%. Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment of R/M NPC. The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemotherapy in advanced ESCC, showing a mOS of 17.7 months and a 3-year OS rate of 29.7%. Results from JUPITER-02 and JUPITER-06 were orally presented at ESMO Asia 2025.SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic...

// Not for distribution to the United States newswire services or for dissemination in the United States // VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) — Copper Quest Exploration Inc. (CSE: CQX; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce that, further to its news release dated December 1, 2025, it has issued an aggregate of 10,142,104 flow-through shares of the Company (the “FT Shares“, and each, a “FT Share“) at a price of $0.19 per FT Share for aggregate gross proceeds of $1,927,000 in connection with its previously announced fully subscribed non-brokered private placement (the “Private Placement“). Each FT Share constitutes a “flow-through share” within the meaning of the Income Tax Act (Canada) (the “Tax Act“) and the gross proceeds of the...

New York, USA, Dec. 05, 2025 (GLOBE NEWSWIRE) — Webus International Limited (“Webus” or the “Company”) provides the following clarification regarding a press release on October 21, 2025, titled “Webus International Limited to Expand Wetour’s Expedia TAAP Partnership with Integration of Expedia Group’s Newly Announced AI Trip Planner and APIs.” (the “Press Release”): The Press Release contains inaccurate descriptions of the scope of Webus’ relationship with Expedia Group, which Webus now seeks to clarify as follows:Webus’ previous engagement with Expedia Group was limited exclusively to its participation in the Expedia Travel Agent Affiliate Program (TAAP).Webus has never had access to Expedia Group’s Smart Trip AI™, B2B APIs, or any other proprietary AI technologies or trademarks nor were Webus...

VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV: SAE | OTCQB: SBLRF) is pleased to announce that the shareholders of the Company provided near unanimous approval of a new omnibus equity incentive plan (the “Equity Incentive Plan”) at the Company’s annual general and special meeting of shareholders held earlier today (the “Meeting”). All other matters advanced at the Meeting, including setting the board at five members, re-election of directors and appointment of BDO Canada LLP as auditor, were also approved near unanimously. The Company adopted the Equity Incentive Plan to provide more flexibility than that provided under the previous stock option plan and restricted share unit plan of the Company (collectively, the “Legacy Plans”). The Equity Incentive Plan provides...

Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced today that on December 4, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its common shares was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until June 2, 2026, to regain compliance with the minimum bid price requirement....

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) — Fly-E Group, Inc. (NASDAQ: FLYE, the “Company”), an electric vehicle company engaged in designing, installing, selling and renting smart electric motorcycles, electric bikes, and electric scooters, announced today that on November 25, the Company received a written notice (the “Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it currently does not satisfy Listing Rule 5250(c)(1), as a result of not having timely filed with the U.S. Securities and Exchange Commission (the “Commission”) its Form 10-Q for the period ended September 30, 2025 (the “Form 10-Q”). The Notice is a notification of deficiency, not of imminent delisting, and has no immediate effect on the listing or trading of the Company’s securities...